Clinical Study

A Phase 2 Evaluation Of Trc105 In Combination With Bevacizumab For The Treatment Of Recurrent Or Progresisve Gliblastoma That Has Progressed On Bevaci

Posted Date: May 15, 2019

  • Investigator: Rekha Chaudhary
  • Specialties:
  • Type of Study: Drug

This study will determine if tumors shrink or if patients survive longer with TRC105 monoclonal antibody treatment in combination with bevacizumab, after his/her tumor has already grown while receiving bevacizumab treatment. The study will also evaluate how well patients tolerate the combination of

Criteria:

Eligible Patients Must Have Glioblastoma That Has Come Back Or Progressed While On Anti-Angiogenic T

Keywords:

105Gm-201, Brain Cancer, Brain Tumor, Gbm, Neuro-Oncology

For More Information:

Uc Cancer Institute
513-584-7698
kastla@ucmail.uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.